Skip to main content
SpringerLink
Log in
Book cover

Tumeurs endocrines thoraciques et digestives pp 195–213Cite as

Traitement antisécrétoire des tumeurs endocrines

  • Chapter

  • 325 Accesses

Abstrait

La grande majorité des travaux concerne les tumeurs digestives. Les tumeurs endocrines digestives (TED), lorsqu’elles sont fonctionnelles, s’accompagnent de symptômes en rapport avec une hypersécrétion hormonale d’origine tumorale. Ces symptômes nécessitent un traitement souvent urgent. Le syndrome hormonal (ou humoral) se rencontre plus volontiers en cas de TED développée aux dépens du bloc duodéno-pancréatique ou de l’intestin moyen (midgut), comprenant l’intestin grêle, la valvule iléocæcale et une partie du côlon droit. Les tumeurs endocrines duodéno-pancréatiques peuvent sécréter de la gastrine (syndrome de Zollinger-Ellison), de l’insuline ou d’autres peptides comme le VIP ou le glucagon. Les tumeurs endocrines sécrétrices de sérotonine intestinales sécrètent surtout de la sérotonine et un certain nombre de kinines. Dans la majorité des cas, l’existence d’un syndrome carcinoïde témoigne de l’existence de métastases hépatiques.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Reubi JC, Kvols LK, Waser B et al. (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res: 5969–77

    Google Scholar 

  2. Krenning EP, Kwekkeboom DJ, Bakker WH et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716–31

    Article  PubMed  CAS  Google Scholar 

  3. Thulin L, Samnegard H, Tyden G et al. (1978) Efendic S. Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 2: 43

    Article  PubMed  CAS  Google Scholar 

  4. Bruns C, Lewis I, Briner U et al. (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol: 707–16

    Google Scholar 

  5. Kvols LK, Moertel CG, O’Connell MJ et al. (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663–6

    PubMed  CAS  Google Scholar 

  6. Souquet JC, Sassolas G, Forichon J et al. (1987) Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 59: 1654–60

    Article  PubMed  CAS  Google Scholar 

  7. Gorden P, Comi RJ, Maton PN et al. (1989) NIH conference. Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110: 35–50

    PubMed  CAS  Google Scholar 

  8. Janson ET, Oberg K (1993) Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32: 225–9

    Article  PubMed  CAS  Google Scholar 

  9. O’Toole D, Ducreux M, Bommelaer G et al. (2000) Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88: 770–6

    Article  PubMed  CAS  Google Scholar 

  10. Eriksson B, Oberg K (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 10Suppl 2: S31–8

    Article  PubMed  Google Scholar 

  11. Ruszniewski P, Ducreux M, Chayvialle JA et al. (1996) Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39: 279–83

    Article  PubMed  CAS  Google Scholar 

  12. Wymenga AN, Eriksson B, Salmela PI et al. (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17: 1111

    PubMed  CAS  Google Scholar 

  13. Rubin J, Ajani J, Schirmer W et al. (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17: 600–6

    PubMed  CAS  Google Scholar 

  14. Ricci S, Antonuzzo A, Galli L et al. (2000) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 11: 1127–30

    Article  PubMed  CAS  Google Scholar 

  15. Ruszniewski P, Ish-Shalom S, Wymenga M et al. (2004) Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 80: 244–51

    Article  PubMed  CAS  Google Scholar 

  16. Kinney MA, Warner ME, Nagorney DM et al. (2001) Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 87: 447–52

    Article  PubMed  CAS  Google Scholar 

  17. Ruskone A, Rene E, Chayvialle JA et al. (1982) Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 27: 459–66

    Article  PubMed  CAS  Google Scholar 

  18. Maton PN, Gardner JD, Jensen RT (1989) Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 34: 28S–39S

    Article  PubMed  CAS  Google Scholar 

  19. Rosenbaum A, Flourie B, Chagnon S et al. (1989) Octreotide (SMS 201–995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion 42: 116–20

    Article  PubMed  CAS  Google Scholar 

  20. Ruszniewski P, Ramdani A, Cadiot G et al. (1993) Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 23: 296–301

    Article  PubMed  CAS  Google Scholar 

  21. Faiss S, Rath U, Mansmann U et al. (1999) Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60: 469–76

    Article  PubMed  CAS  Google Scholar 

  22. Oberg K (2004) Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 80Suppl 1: 57–61

    PubMed  Google Scholar 

  23. Norton JA, Fraker DL, Alexander HR et al. (1999) Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341: 635–44

    Article  PubMed  CAS  Google Scholar 

  24. Chandrasekharappa SC, Guru SC, Manickam P et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404–7

    Article  PubMed  CAS  Google Scholar 

  25. Blanchi A, Delchier JC, Soule JC et al. (1982) Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet 2: 1223–4

    Article  PubMed  CAS  Google Scholar 

  26. Oberg K, Lindstrom H (1983) Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole. Lancet 1: 66–7

    Article  PubMed  CAS  Google Scholar 

  27. Hirschowitz BI, Simmons J, Mohnen J (2001) Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 15: 1795–806

    Article  PubMed  CAS  Google Scholar 

  28. McArthur KE, Collen MJ, Maton PN et al. (1985) Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology 88: 939–44

    PubMed  CAS  Google Scholar 

  29. Cadranel JF, Ruszniewski P, Elouaer-Blanc L et al. (1989) Long-term efficacy and tolerability of omeprazole in 20 patients with severe Zollinger-Ellison syndrome. Gastroenterol Clin Biol 13: 654–62

    PubMed  CAS  Google Scholar 

  30. Maton PN, Vinayek R, Frucht H et al. (1989) Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 97: 827–36

    PubMed  CAS  Google Scholar 

  31. Frucht H, Maton PN, Jensen RT (1991) Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 36: 394–404

    Article  PubMed  CAS  Google Scholar 

  32. Metz DC, Strader DB, Orbuch M et al. (1993) Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 7: 597–610

    Article  PubMed  CAS  Google Scholar 

  33. Paul G, Ramdani A, Mignon M et al. (1994) Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal. Gastroenterol Clin Biol 18: 695–701

    PubMed  CAS  Google Scholar 

  34. Metz DC, Soffer E, Forsmark CE et al. (2003) Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol 98: 301–7

    Article  PubMed  CAS  Google Scholar 

  35. Carswell CI, Goa KL (2001) Rabeprazole: an update of its use in acid-related disorders. Drugs 61: 2327–56

    Article  PubMed  CAS  Google Scholar 

  36. Metz DC, Sostek MB, Ruszniewski P et al. (2007) Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric hypersecretion. Am J Gastroenterol 102: 1–7

    Article  Google Scholar 

  37. Saeed ZA, Norton JA, Frank WO et al. (1989) Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 96: 1393–402

    PubMed  CAS  Google Scholar 

  38. Vinayek R, Frucht H, London JF et al. (1990) Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology 99: 10–6

    PubMed  CAS  Google Scholar 

  39. Lew EA, Pisegna JR, Starr JA et al. (2000) Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118: 696–704

    Article  PubMed  CAS  Google Scholar 

  40. Wolfe MM, Jensen RT (1987) Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 317: 1200–9

    PubMed  CAS  Google Scholar 

  41. Pisegna JR, Norton JA, Slimak GG et al. (1992) Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 102: 767–78

    PubMed  CAS  Google Scholar 

  42. Miller LS, Vinayek R, Frucht H et al. (1990) Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 98: 341–6

    PubMed  CAS  Google Scholar 

  43. Mignon M, Cadiot G (1998) Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. J Intern Med 243: 489–94

    Article  PubMed  CAS  Google Scholar 

  44. Cadiot G, Houillier P, Allouch A et al. (1996) Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d’Étude du Syndrome de Zollinger-Ellison. Gut 39: 273–8

    Article  PubMed  CAS  Google Scholar 

  45. Norton JA, Cornelius MJ, Doppman JL et al. (1987). Effect of parathyroidectomy in patients with hyperparathyroidism, Zollinger-Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery 102: 958–66

    PubMed  CAS  Google Scholar 

  46. Termanini B, Gibril F, Sutliff VE, Yu F et al. (1998). Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med 104: 422–30

    Article  PubMed  CAS  Google Scholar 

  47. Lamberts R, Creutzfeldt W, Struber HG et al. (1993). Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 104: 1356–70

    PubMed  CAS  Google Scholar 

  48. Larsson H, Hakanson R, Mattsson H et al. (1988) Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 16: 267–72

    Article  PubMed  CAS  Google Scholar 

  49. Lehy T, Cadiot G, Mignon M et al. (1992) Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33: 1275–9

    Article  PubMed  CAS  Google Scholar 

  50. Peghini PL, Annibale B, Azzoni C et al. (2002) Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology 123: 68–85

    Article  PubMed  Google Scholar 

  51. Cadiot G, Mignon M, Ruszniewski P et al. (2005) Traitement symptomatique des tumeurs endocrines pancréatiques. Traité de pancréatologie clinique. Paris: Médecine-sciences Flammarion, Paris. p 318

    Google Scholar 

  52. Gill GV, Rauf O, MacFarlane IA (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73: 640–1

    PubMed  CAS  Google Scholar 

  53. Modlin IM, Kidd M, Latich I et al. (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128: 1717–51

    Article  PubMed  Google Scholar 

  54. Fjallskog ML, Sundin A, Westlin JE et al. (2002) Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 19: 35–42

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de gastro-entérologie, Hôpital Beaujon, 100, boulevard du Général-Leclerc, 92110, Clichy

    O. Corcos & P. Ruszniewski

  2. Service de gastro-entérologie, CHU d’Angers, 4, rue Larrey, 49933, Angers Cedex 9

    D. O’Toole

Authors
  1. O. Corcos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. O’Toole
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Ruszniewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Corcos, O., O’Toole, D., Ruszniewski, P. (2008). Traitement antisécrétoire des tumeurs endocrines. In: Tumeurs endocrines thoraciques et digestives. Springer, Paris. https://doi.org/10.1007/978-2-287-35574-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-35574-5_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-35573-8

  • Online ISBN: 978-2-287-35574-5

Publish with us

Policies and ethics

Search

Navigation